Long-term Treatment with Pegvisomant: Observations from 2090 Acromegaly Patients in ACROSTUDY.

Michael Buchfelder¹, Aart-Jan van der Lely², Beverly MK Biller³, Susan M. Webb⁴, Thierry Brue⁵, Christian J. Strasburger⁶, Ezio Ghigo⁷, Cecilia Camacho-Hubner⁸, Kaijie Pan⁹, Joanne Lavenberg⁹, Peter Jonsson¹⁰, Juliana H. Hey-Hadavi⁸

Author Affiliations:
¹Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Germany
²Department of Medicine, Erasmus University MC, Rotterdam, the Netherlands
³Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
⁴Endocrinologia (Malalties de la Hipòfisi), Hospital Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
⁵Department of Endocrinology, Centre de Référence des Maladies Rares d’Origine Hypophysaire, Hôpital de la Conception, Marseille, France
⁶Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Charité Universitätsmedizin, Campus Mitte, Berlin, Germany
⁷University Hospital Città Salute e Scienza, Turin, Italy
⁸Endocrine Care Global Medical Affairs, Pfizer Inc., New York City, New York, USA
⁹Endocrine Care Global Clinical Affairs, Pfizer Inc, Collegeville, PA, USA
¹⁰Endocrine Care, Pfizer Health AB, Sollentuna, Sweden

Short Title: Findings from pegvisomant use in ACROSTUDY

Keywords: acromegaly, pegvisomant, observational study

Corresponding Author: Prof. Michael Buchfelder

Email: Michael.Buchfelder@uk-erlangen.de

Word Count: 5520
Abstract

Objectives: ACROSTUDY is an international, non-interventional study of acromegaly patients treated with pegvisomant (PEGV), a growth hormone receptor antagonist and has been conducted since 2004 in 15 countries to study the long-term safety and efficacy of PEGV. This report comprises the second interim analysis of 2090 patients as of May 12, 2016.

Methods: Descriptive analyses of safety, pituitary imaging and outcomes on PEGV treatment up to 12 years were performed.

Results: Prior to starting PEGV, 96% of patients had reported surgery, radiation, medical therapy or any combinations of those. At start of PEGV, 89% of patients had IGFI levels above the ULN. The percentage of patients with normal IGFI levels increased from 53% at year 1 to 73% at year 10, and the average daily dose of PEGV increased from 12.8mg (year 1) to 18.9mg (year 10). A total of 4832 adverse events (AEs) were reported in 1137 patients (54.4%), of which 570 were considered treatment-related in 337 patients (16.1%). Serious AEs were reported in 22% of patients, of which 2.3% were considered treatment-related. Locally reported MRIs showed most patients (72.2%) had no change in tumor size relative to the prior scan; 16.8% had a decrease, 6.8% an increase, and 4.3% both. In patients with normal liver tests at PEGV start, an ALT or AST elevation of >3x ULN at any time point during their follow up was reported in 3%.

Conclusions: This second interim analysis confirms that long-term use of PEGV is an effective and safe treatment in patients with acromegaly.
Introduction

Acromegaly is a rare disease caused by hypersecretion of growth hormone (GH) and insulin-like growth factor I (IGFI) due to a GH-secreting pituitary adenoma. Pegvisomant (PEGV) is a pegylated growth hormone analogue with eight amino acid substitutions in growth hormone–binding site 1 and the substitution of glycine for alanine at position 120, resulting in both enhanced affinity for the growth hormone receptor and prevention of functional growth hormone–receptor signaling. PEGV acts as a growth hormone (GH) receptor antagonist. It has been available for the medical treatment of acromegaly for more than 15 years. The initial pivotal studies included approximately 200 patients with acromegaly and demonstrated that PEGV was effective in relief of symptoms and normalization of IGFI in up to 97% of patients. Because of the unique mechanism of action as a GH-receptor antagonist, there was a need to collect additional data outside of the clinical trial program to better understand the safety and efficacy profile of PEGV in acromegaly patients. ACROSTUDY was developed to provide these long-term data in a real world clinical setting.

The first real world data on PEGV treatment came from the German Prospective Observational Study (GPOS), initiated in 2003, which reported data from over 300 patients. It provided valuable clinical information and contributed to the development of the global ACROSTUDY. Most patients from GPOS have been included into ACROSTUDY and have added to the long-term follow up data.

ACROSTUDY was initiated in 2004 to serve as an international, post-authorization, safety surveillance study and was open to all patients with acromegaly treated with PEGV. The main study objective was to monitor the long-term safety and outcome of PEGV treatment in patients with acromegaly. Patients were enrolled in the study on an ongoing basis and the investigators reported data from follow up visits in electronic case report forms. The first two publications from ACROSTUDY reported on data from the study at years 4 and 5. In these analyses, no unexpected safety concerns were seen, but it was noted
that the IGFI normalization rate was lower than observed in the pivotal clinical trials. It was concluded that longer-term follow up and additional patient enrolment would provide a better understanding of PEGV treatment in clinical practice\textsuperscript{9,10}. The first interim analysis of this study was performed five years after the start of ACROSTUDY and included data collected on 1288 patients who were enrolled as of December 31, 2009\textsuperscript{11}. This analysis noted low rates of increased pituitary tumor size, elevated liver enzymes, and lipodystrophy. Subsequent publications of subgroups in ACROSTUDY focused on PEGV use as monotherapy and most recently of PEGV in combination with somatostatin analogs and/or dopamine agonists\textsuperscript{12,13}. In addition, the availability of data from countries that contributed larger patient cohorts has resulted in several country-specific publications from France, Italy and Spain\textsuperscript{14,15,16}.

This report comprises the second interim analysis on all patients in the main study as of May 12, 2016. It describes the results of PEGV treatment in ACROSTUDY and reports the long-term experience for up to 12 years in the patients who were part of the original cohort.

**Methods**

**Study Design**

This open label, global, observational study was conducted to monitor the long-term safety and outcomes of PEGV treatment on a large group of patients with acromegaly in a real world clinical practice setting. Although the protocol made recommendations for the timing and type of assessments, no additional diagnostic or monitoring procedures beyond routine clinical practice were required as part of the study. Due to the observational nature of the study, PEGV dosing, frequency and titration were determined by the investigator based on clinical judgment and local practice. Descriptions of the study methods have been published previously\textsuperscript{8,11}.

**Patients and data collection**
Patients with acromegaly treated with PEGV were enrolled on an ongoing basis after meeting all inclusion and exclusion criteria. Patients who were participating in other investigational trials for acromegaly, required surgery to decompress the tumor or non-medical therapy because of visual field loss, cranial nerve palsies or intracranial hypertension, were not eligible for enrolment. Pediatric patients (<18 years of age) could be included in all countries except for Italy and the US.

Data were collected by the site investigators from the medical records at baseline; information gathered at each routine clinical visit was then added longitudinally. The parameters were captured on electronic case report forms using a web-based tool. Baseline was defined as start of PEGV, regardless of time of enrolment into the study; as noted, some patients were already taking PEGV when they were enrolled (Figure 1). Reported information included findings from baseline and follow up medical history, physical exams, laboratory testing and pituitary imaging. Adverse events (AEs) were classified according to terms from the Medical Dictionary of Regulatory Activities (MedDRA) version 14.1. For serious adverse events (SAEs), the reporting period encompassed the date of informed consent through 28 calendar days after the last dose of PEGV. Remote and/or on-site monitoring was performed according to local policies and sites were asked to provide additional information if necessary. If local MRI reports indicated a change in pituitary tumor size (increase or decrease) the scans were to be sent for central assessment as described in a previous publication. The study was approved by independent local ethical committees at the investigator sites and conducted in accordance with all local legal, regulatory and ethical requirements, including informed consent signature and process prior to any data capture.

**Statistical Methods**

There were no pre-specified statistical hypotheses tested in this study, with all data collected regarding acromegaly history and in follow-up after PEGV start to be evaluated and summarized descriptively. The full analysis set was defined as all patients who enrolled in ACROSTUDY and received at least one PEGV dose. Importantly, because baseline was defined as the start of PEGV treatment, which could be prior
to enrolment into ACROSTUDY, clinical data reported at baseline were included in the analysis in order to capture as much information as possible during treatment. The following visit labels were used for data reporting: Baseline (from 6 months before to 1 day after PEGV start, except for MRI scans which allowed 1 year before and 1 day after PEGV start), Month 6, Month 12 and yearly visits thereafter.

Categorical variables were summarized by presenting the frequency distribution and percent, which were based on the total number of patients with an observed measure of interest at a specified time point or over a specified time frame. Descriptive analyses of safety, tumor status and treatment outcomes for all patients treated with PEGV were performed. Among the patients with liver tests (AST/ALT) reported at baseline, a “shift analysis” was performed to determine how many results shifted between normal, mildly elevated or abnormal; abnormal was defined as AST or ALT levels > 3 times the upper limit of normal (ULN). Patients who had either AST or ALT measured at baseline and at any time during the course of PEGV treatment were included in the shift analysis.

Results

Participants

As of May 12, 2016, data from 2090 patients were available from 14 European countries and the US (Figure 2). Among the 2090 patients enrolled in ACROSTUDY, 466 (22.3%) were still ongoing subjects at the time of data freeze in May 12, 2016 and 1624 (77.7%) subjects had concluded their participation prior to this time point due to closure of study sites, exiting of study or being deceased. There were 78 (3.7%) deaths reported. All 2090 (100%) patients were included in the safety population for analysis of AEs including duration, severity and causality. A total of 2080 (99.5%) patients had laboratory data recorded and 2045 patients (97.8%) were evaluated for pituitary imaging.

Patient Characteristics

Mean PEGV treatment duration was 7.6 years (y) (median 8.1, range: 0-19.1 y). Patients were followed in ACROSTUDY for a mean of 6.3 y (median 6.8, range -0.1 to +12.1 y). Most patients were Caucasian
(93%) and the proportion of males and females was similar (51 vs 49%). The mean age at diagnosis of acromegaly was 42.1 y (median 41.1, range: 1.7-83.7 y) and the mean age at the start of PEGV (Baseline) was 49.5 y (median 49.8, range: 3.9-85.6 y). Males were slightly younger at diagnosis (40.8 years vs 43.3 years) and were also started on PEGV at slightly younger age (48.3 years vs. 50.8 years). There were 1572 patients (75%) who started PEGV prior to enrolment into ACROSTUDY with the mean time from start of PEGV treatment to start of ACROSTUDY of 598 days (median 345.5; range -970 to +3944 days). The remaining subjects started PEGV treatment at the same time as enrolment in ACROSTUDY. Patients were grouped by age category based on the age at diagnosis of acromegaly as well as start of PEGV. There were 46 patients (2.2%) diagnosed with acromegaly before the age of 18, while 15 patients (0.7%) started PEGV before the age of 18. On the other side of the spectrum, there were 47 patients (2.2%) diagnosed after age 70, while 166 patients (7.9%) started PEGV after the age of 70.

**Acromegaly treatment**

Figure 3 summarizes the main treatment paradigms used in the patients prior to initiation of PEGV. Prior to starting PEGV, 96% of patients had undergone surgery, radiation, medical therapy or any combinations of those. Among the 76% of patients who had surgery, most (96.4%) had trans-sphenoidal surgery (TSS). Among the 26% of patients who had radiation, conventional was reported in 49% and stereotactic in 51% of cases. After PEGV start, 8.6% of patients reported subsequent pituitary surgery (TSS in 98% of these cases). Among the 13.1% of those who were reported to have received radiation after initiation of PEGV, most (77%) had stereotactic radiation.

**Co-morbidities**

Acromegaly-associated co-morbidities were captured during three time periods: before PEGV start, after the start of PEGV but before ACROSTUDY start, as well as during enrolment in ACROSTUDY (Figure 4). In the majority of patients (n=1827, 87.4%) at least one co-morbidity was reported before starting PEGV.
and patients could have had more than one co-morbidity reported. Of these patients, 66% had been treated with a somatostatin analogue (SSA) as the only medication prior to starting PEGV, while 31% were reported to have been treated with SSA in combination with another medication, in most cases a dopamine agonist.

The overall percentage of patients with all co-morbidities combined and the most common co-morbidities before PEGV start, after PEGV start and before enrolment into ACROSTUDY and after ACROSTUDY start are shown in Figure 4. Before PEGV start hypertension was reported in more than half of patients and diabetes in almost one third of patients.

Included under “Tumors” are both benign and malignant tumors at the three time periods (respectively) in thyroid (18%, 7.3%, 6.7%), colon (14.9%, 9.6%, 7.3%); prostate (2.3%, 2.5%, 1.3%); and breast (3.2%, 1.7%, 0.7%);

*Pituitary Deficiencies*

In patients with information reported about pituitary function, deficiencies at PEGV start were most commonly observed for pituitary-gonadal function (230 of 607 patients; 37.9%), followed by thyroid function (185 of 635 patients; 29.1%), adrenal function (156 of 551 patients; 28.3%), and diabetes insipidus (8 of 420 patients, 2%). In previously irradiated patients (n=542, 26%), multiple pituitary deficiencies were common.

Most patients (88.8 %) had no genetic syndromes associated with the diagnosis of acromegaly, and such disorders were noted only in a small number of patients. Acromegaly was reported in association with an inherited syndrome in 4.9 % of patients; these included Multiple Endocrine Neoplasia (MEN type 1) (24 patients, 1.1%), McCune Albright syndrome (20 patients, 1%), familial acromegaly (9 patients, 0.4%) or other associated syndromes (46 patients, 2.2%).

**Efficacy and Safety**
At PEGV start, most (n=1734, 83%) patients were administered PEGV once daily, while the others were prescribed PEGV either once weekly (n=180, 8.6%) or between 2-6 times per week (n=164, 7.8%). Most patients (n=1439, 68.9%) had a starting daily dose of 10 to <15 mg, while 57 patients (2.7%) started at a dose ≥ 30 mg. Although daily dosing of 10 to <15 mg remained initially the most common, over time, doses were up-titrated. For example, at year 1, 20.6% received 15 to <20 mg daily vs 7.3% at PEGV start and 18.7% received 20 to <25 mg vs 5.8% at PEGV start. We also observed a steady increase in the number of patients receiving ≥30mg/d from 2.7% to 20.6% at year 12 (Figure 5). While most patients (55.5%) received the medication as monotherapy at the start of PEGV treatment, over time that percentage decreased and combination therapy was increasingly employed as recently reported\textsuperscript{13}.

**Efficacy**

At the start of PEGV, only 11% of patient had IGFI levels in the normal range. The percentage of patients with normal IGFI levels increased from 53% at year 1 to 73% at year 10 (Figure 6). This increased level of control was accompanied by an increase in the mean daily dose of PEGV from 12.8 mg at year 1 to 18.9 mg at year 10.

**Safety**

A total of 4832 AEs was reported in 1137 patients (54.4%), and the most common AE reported was “IGFI increased” (10.5% of patients), which was associated with the diagnosis of acromegaly. The next most commonly reported AEs were headache (4.9%), vitamin-D deficiency (4.6%) and arthralgia (3.7%). In total, 570 AEs considered treatment-related were experienced by 337 patients (16.1%). Among these treatment-related AEs (in ≥ 2 patients) were liver test elevations (transaminases increased [n=30], hepatic enzyme increase [n=18], ALT increase [n=18], AST increase [n=5]), followed by gastro-intestinal disorders (n=26), asthenia (n=9), injection site conditions (lipohypertrophy [n=31], reactions [n=16], erythema [n=3], lipodystrophy [n=5]), headache (n=7), fatigue (n=6) and pituitary tumor recurrence (n=9). SAEs were experienced in 22% of patients, of which 2.3% were considered treatment-related.
The most frequently reported SAEs were pituitary tumor recurrence (1%), osteoarthritis (1%), and death (1%). Overall, 146 patients (7%) were discontinued from ACROSTUDY due to SAEs, including 78 patients due to death and 24 patients discontinuing due to treatment-related SAEs. The most common cause of death was cardiovascular disorders and all deaths were considered unrelated to the treatment. Deaths occurred due to variety of reasons, most commonly cardiac disorders such as cardiac failure (5), myocardial infarction/acute MI (4), cardiac arrest/sudden cardiac death (4). Different types of cancer were reported in 8 patients. The most common SAEs resulting in discontinuation were recorded as general disorders (i.e. asthenia, adverse drug reaction, death, disease progression) and administration site conditions. The number of discontinuations due to non-serious AEs and the severity of AEs were not captured for this study.

Of the 2045 patients analyzed for pituitary imaging, 1712 patients had at least 1 local pituitary imaging result reported in follow up after PEGV start. Reports of locally-assessed MRIs showed that most patients (72.2%) had no change in tumor size relative to the prior scan; 16.8% had decrease in tumor size, 6.8% had an increase, and 4.3% had both an increase and decrease. Changes in tumor size were reported as adverse events for 90 patients (4.3%) of which 21 (1%) were considered treatment-related. Of those listed as treatment-related, 8 patients (0.4%) had study drug withdrawn. As previously reported, any pituitary MRIs showing a significant change were to be sent for centralized re-assessment. Among patients who had an increase as per local reading (n=119), the central reading confirmed an increase in 29 patients; while in 23 patients there was no change.

Hepatobiliary-related AEs were reported for 9.8% of patients, of which 4.2% were considered treatment-related. Drug withdrawal for this reason was reported in 9 patients (0.4%). Of the 1094 patients with normal baseline AST and ALT measurements, most (62%), continued to have normal AST and ALT values during follow up, while in 3% at least one AST or ALT value >3x ULN was reported. Of the 89 patients entering the study with a mildly elevated AST or ALT values between 1-3X ULN, 30 patients
(34%) shifted downward to a normal AST and ALT during follow up on PEGV treatment, 41 (46%) remained within their baseline measurement range, while 10% had ALT or AST >3x ULN. Of the 7 patients entering the study with an AST or ALT value 3-5X ULN, 3 shifted to normal, 3 shifted to mildly abnormal (between 1-3X ULN) and one patient shifted to >5X ULN while on PEGV treatment.

Injection site reactions were reported for 71 patients (3.4%) and the majority (65 patients, 3.1%) were considered by the investigator to be treatment-related. One case of lipohypertrophy was reported as a SAE. In an additional 4 patients, injection site reactions were reported as “co-morbidities” and not as adverse event.

Despite the requirement of adequate birth control, a total of 15 pregnancies (3 of which occurred in the patient’s partner) were reported. The outcomes of these pregnancies included 9 childbirths, 3 abortions and 3 unknown. All childbirths were reported to have resulted in a normal outcome. Data from pregnancies in ACROSTUDY have been previously reported.

**Discussion**

This observational study of treatment with PEGV in acromegaly provided an opportunity to evaluate a large “real world” data set (n=2090) over an average of 7.6 years of PEGV treatment. Patients were treated according to local practice with no specific protocol procedures or visit dates required and laboratory tests were performed locally. Prior to starting PEGV, 96% of subjects had undergone surgery, radiation, medical therapy or combinations of those, which in the majority (89%) did not result in adequate IGFI control. Most patients entered ACROSTUDY after being treated with PEGV for a median duration of almost one year. Serum IGFI normalization rate increased over time (up to 73% in year 10). While this rate is somewhat lower than what was seen in clinical trials, it is similar to what was observed in the first interim analysis and other ACROSTUDY publications. Possible explanations for the discrepancy in IGFI control between clinical trials and ACROSTUDY include the use of different criteria
for IGFI normalization, absence of a dose titration scheme (as typically done in clinical trials), use of a
variety of IGFI assays, the fact that a number of patients with an elevated IGFI were not titrated up to
the maximal allowed daily dose according to the label, and that the normalization rate was assessed on
a yearly basis in this database rather than at only one time point typical for the primary outcome in
clinical trials. In real world setting adherence may fluctuate and measurements of adherence were not
part of this study. Therefore, normalization rate methods are not comparable to those observed in
clinical trials. Tritos et al\textsuperscript{19} also recently proposed potential reasons for this discrepancy which included
insufficient dose titration, inadequate patient adherence, possible adverse effects, and economic
reasons limiting dose escalations. It was also noted that over time more patients were treated with
doses $\geq 30 \text{mg/day}$. In a recent analysis of ACROSTUDY looking at high dose treatment in 56 patients, it
was observed that patients who needed higher doses of PEGV have more aggressive disease\textsuperscript{20}. In
ACROSTUDY there was no indication of any “escape” phenomenon, i.e. elevation of IGFI after initial
normalization.

At the time of PEGV start 89\% of patients had IGFI$>$ULN and comorbidities at PEGV start were common.
In an analysis of the Liège Acromegaly Survey Database of 3173 patients with acromegaly, Petrossians et
al\textsuperscript{21} described the presence of diabetes in 27.5\% and hypertension in 28.8\% of patients at the time of
diagnosis of acromegaly. In the current study, those comorbidities were reported higher with diabetes in
32\% and hypertension in 51\% of patients at the start of PEGV. These differences could be due to the
longer duration of acromegaly in an older cohort, but another possibility is that PEGV may have been
more commonly prescribed in patient with metabolic comorbidities such as diabetes and hypertension.

In subjects with normal liver tests at PEGV start, an ALT or AST elevation of $>3\times$ ULN at any time point
during their follow up in ACROSTUDY was reported in 3\% of subjects (Table 1). In 9 patients (0.4\%) PEGV
was withdrawn due to liver test elevations. Notably, most elevations were transient and there were no
reports of liver failure. In an earlier study by Biering et al\textsuperscript{22}, it was observed that in 12 patients with
transaminases elevations during treatment with PEGV, 5 cases could be attributed to gallstones and in 4 patients transaminases normalized despite continuation of PEGV. Kasuki et al\textsuperscript{23} reported the experience with pegvisomant in a single Brazilian center and observed in 2 of their 27 patients (7.4%) mild (1.5 and 2.3 xULN) and transitory elevations of liver enzymes. In a report of Japanese patients with acromegaly, Shimatsu et al\textsuperscript{24} reported ALT and AST increases in 3 (2 mild and 1 moderate) of 16 patients (16.7%), which resolved after discontinuation of pegvisomant. The results of this analysis are consistent with observations from the initial clinical trials and prior long-term observational data\textsuperscript{3,8, 10-15,22}. In the current analysis of the liver test results, the majority of patients with mild elevations of ALT or AST (1-3xULN) did not report worsening of liver tests at any time during follow up. Monitoring of liver test during PEGV treatment should occur. However, transient elevations especially in the early months of therapy may have been missed due to the non-interventional nature of the study, the frequency of the visits and patients prone to liver test elevations may not have been treated with PEGV.

The pituitary MRI findings in this analysis were consistent with the previously reported data for ACROSTUDY \textsuperscript{5,9-16}. In a retrospective analysis of 75 patients in two centers in the UK, one patient was reported to have significant tumor size increase; however, this tumor was growing prior to PEGV treatment\textsuperscript{17}. Buhk et al\textsuperscript{25} published the results of a German prospective study examining the long-term course of adenoma volumes during PEGV treatment by MRI. They observed tumor volume increase >25% in 3 of 61 patients (4.9%) during the first year of enrolment. All 3 patients had octreotide treatment withdrawn prior to PEGV. In ACROSTUDY, prior to PEGV initiation, 65.9% of patients were treated with SSA only, while 31.3% were treated with SSA plus another treatment (most cases dopamine agonist). Due to the observational nature of our study and timing of MRI assessments, we were not able to determine whether the pituitary volume increases predated the PEGV treatment or if they may have been temporally associated with the change of medication and reflected rebound growth after SSA.
withdrawal. As was previously reported, a limitation of the pituitary imaging assessment was that not all scans that showed a change, were submitted for central reading.

ACROSTUDY provided an opportunity to evaluate long-term data in a variety of clinical settings across 15 countries. Although ACROSTUDY is maintained as a global database, certain countries have contributed more patients and data than others (Figure 2). In a publication by Chanson et al, the data of 292 French patients entered into ACROSTUDY were evaluated. They found similar findings as reported in this analysis, however they observed a mean weight increase of 3 kg over 5 year period and a significant decrease of fasting blood glucose over time. The previously reported Italian experience in 341 patients from 25 centers included at that time in ACROSTUDY, reported that treatment with PEGV showed high efficacy and safety similar to the global cohort. In Italy, PEGV is available as third line therapy (after surgery or radiotherapy and SSA failure) and therefore in patients who had failed to normalize IGFI with these treatment modalities. Nonetheless they reported that 70.9% of patients were found to have normal IGFI levels at year 6. The publication of Spanish data from 199 patients also confirmed a favorable safety and efficacy profile and showed similar IGFI control as reported globally. However, PEGV dosing was lower in that report, and 52% of the patients received combination treatment. In the current analysis, country-specific data were not examined separately. Differences in treatment practice, standards of care, and access to medications may have influenced this analysis; the countries that contributed the majority of patients in ACROSTUDY were in Western Europe.

There are many strengths of ACROSTUDY, including large patient numbers, wide geographic representation, and a long-term patient follow up period. Nevertheless, observational, surveillance studies like ACROSTUDY have limitations. For example, the fact that patients were enrolled into the study regardless of when they started PEGV treatment (i.e. did not need to be treatment-naive) meant that many patients did not have baseline data entered before starting the medication. This was partially
addressed by retrospective collection of additional relevant clinical information, such as co-morbidities from the source documents, when available. Safety data may have been missed early in treatment in those patients who had already been taking PEGV for a long time prior to enrolment in ACROSTUDY. In addition, no data about early side effects would have been obtained for patients who stopped PEGV before being considered for the study, and therefore never enrolled in ACROSTUDY. An additional limitation was possible underreporting of data regarding enrolled patients. This is because ACROSTUDY captured routine clinical care that was provided according to individual clinic/physician practice and data entry depended on the patient’s visits and level of follow up. After discontinuation of PEGV for any reason most patients also discontinued participation in ACROSTUDY. The current study did not allow us to determine patients were stopped because they did not response to PEGV treatment or to capture any possible reason for discontinuation. Finally, any bias in reporting or in patient selection (i.e. patients in which PEGV is effective) cannot be excluded.

Conclusions

ACROSTUDY provides a robust global perspective on real world outcomes of PEGV treatment and numerous investigators (>200) in 15 countries have contributed information from their clinic patients to this robust database. This second interim analysis, after more than a decade of ACROSTUDY enrolment, performed on 2090 patients, confirms that long-term use of PEGV can be an effective and safe treatment in patients with acromegaly. The low occurrence of pituitary tumor enlargement, new liver test elevations and site administration reactions was reassuring.

ACROSTUDY has provided long-term safety information that complements the safety data obtained from clinical trials. The larger numbers of subjects, including those who may not have been eligible for enrolment in clinical trials, and the longer duration of follow up, allowed for a better understanding of overall use and the safety profile of PEGV.
Disclosures:


Acknowledgements:

We sincerely thank all investigators, sub-investigators and study coordinators and patients for their participation and contributions to ACROSTUDY. This study has been sponsored by Pfizer Inc.

References


Figure 1  Data Collection and Flow

Before Pegvisomant Start
- Pituitary Imaging
- Laboratory Tests
- Comorbidities

Pegvisomant Treatment
- Pituitary Imaging
- Laboratory Tests
- Co-morbidities

ACROSTUDY enrollment
- Pituitary Imaging
- Laboratory Tests
- Co-morbidities
- Adverse Events (AEs)

Pegvisomant Start (Baseline)

ACROSTUDY Start

Database Freeze
May 12, 2016
Figure 2  Country distribution (%)
Figure 3 Treatment for acromegaly prior to initiation of PEGV

- Medical Therapy only
  - n=376 (18%)

- Medical & Surgery
  - n=1000 (47.8%)

- Medical, Surgery & Radiation
  - n=464 (22.2%)

- Radiation & Surgery
  - n=35 (1.7%)

- Surgery only
  - n=90 (4.3%)

- Radiation only
  - n=1 (0%)
Figure 4  Most Commonly Reported Acromegaly-Related Co-Morbidities
Figure 5 Pegvisomant Treatment by Year (daily dose)
Figure 6  IGF-I normalization over time

<table>
<thead>
<tr>
<th>Year</th>
<th>IGF-I normal (%)</th>
<th>IGF-I &gt; ULN (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start</td>
<td>11.4</td>
<td>88.5</td>
</tr>
<tr>
<td>YR1</td>
<td>53</td>
<td>44</td>
</tr>
<tr>
<td>YR2</td>
<td>57.4</td>
<td>40.2</td>
</tr>
<tr>
<td>YR3</td>
<td>58.2</td>
<td>38.9</td>
</tr>
<tr>
<td>YR4</td>
<td>60</td>
<td>37.8</td>
</tr>
<tr>
<td>YR5</td>
<td>62.4</td>
<td>35.4</td>
</tr>
<tr>
<td>YR6</td>
<td>64</td>
<td>34.3</td>
</tr>
<tr>
<td>YR7</td>
<td>60.6</td>
<td>37.9</td>
</tr>
<tr>
<td>YR8</td>
<td>64.2</td>
<td>34.1</td>
</tr>
<tr>
<td>YR9</td>
<td>65.6</td>
<td>30.6</td>
</tr>
<tr>
<td>YR10</td>
<td>73.3</td>
<td>25.7</td>
</tr>
</tbody>
</table>

Copyright © 2018 European Society of Endocrinology